Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients
Sponsored by Methodist Health System
About this trial
Last updated 2 years ago
Study ID
023.HEP.2023.D
Status
Unknown
Type
Observational
Placebo
No
Accepting
18+ Years
All Sexes
Trial Timing
Ended a year ago
What is this trial about?
Determine the levels of Donor-derived (dd)cell-free DNA(cfDNA )in liver transplant recipients with normal liver function tests (LFTs) indicating stable immunosuppression status (IS). Based on this range use the dd-cfDNA levels to determine over or under IS in liver transplant patients to make changes to their IS medication regimen.
What are the participation requirements?
Inclusion Criteria
1. Age: ≥18 years
2. The patient underwent a liver transplant.
3. The patient at least has one level of dd-cfDNA documented
Exclusion Criteria
* Patient not meeting the inclusion criteria will be excluded.